Fluxus

Executive Summary

Fluxus is a San Francisco-based synthetic biology company pioneering bioanalytical solutions that achieve ultrasensitivity while detecting a broad range of biomolecular targets. Its low-complexity configurations are designed to be adaptable to any testing environment, potentially enabling point-of-care diagnostics, environmental monitoring, or bioprocess control. Founded in 2016, the company operates in the metabolic engineering and synthetic biology space, developing proprietary detection platforms that combine high specificity with operational simplicity. While still private and with limited public information, Fluxus’s technology holds promise for applications requiring rapid, sensitive, and decentralized biomolecular analysis. The company’s approach addresses key limitations of existing bioanalytical tools, such as cost, complexity, and scalability, positioning it for growth in the expanding biosensing market.

Upcoming Catalysts (preview)

• TBDNext funding round or strategic partnership70% success
• TBDPublication of validation data in peer-reviewed journals60% success
• TBDCommercial launch of first product or beta release50% success